Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
September 28, 2023 08:30 ET
|
Vericel Corporation
Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared...
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
September 20, 2023 16:30 ET
|
Vericel Corporation
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid...
Vericel to Present at the Morgan Stanley Global Healthcare Conference
September 06, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
August 02, 2023 07:55 ET
|
Vericel Corporation
Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year...
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
July 20, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
May 10, 2023 07:55 ET
|
Vericel Corporation
Record First Quarter Total Revenue of $41 Million MACI Revenue Increased 32% to $34.2 Million Full-Year 2023 Revenue Guidance Raised to $184-$192 Million Conference Call Today at 8:30am Eastern...
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
April 26, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
February 28, 2023 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
February 23, 2023 07:55 ET
|
Vericel Corporation
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million, with MACI Revenue of $132 Million Full-Year 2023 Total Revenue Guidance...
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
February 09, 2023 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...